| Primary |
| Breast Cancer |
56.5% |
| Breast Cancer Metastatic |
12.4% |
| Gastric Cancer |
5.3% |
| Hypertension |
5.2% |
| Prophylaxis |
3.1% |
| Pain |
3.0% |
| Nausea |
2.4% |
| Product Used For Unknown Indication |
1.8% |
| Head And Neck Cancer |
1.7% |
| Anxiety |
1.0% |
| Breast Neoplasm |
1.0% |
| Malignant Glioma |
0.9% |
| Neoplasm |
0.9% |
| Asthma |
0.9% |
| Depression |
0.8% |
| Insomnia |
0.8% |
| Drug Use For Unknown Indication |
0.7% |
| Metastases To Central Nervous System |
0.6% |
| Diarrhoea |
0.6% |
| Epilepsy |
0.5% |
|
| Vomiting |
18.6% |
| Pyrexia |
14.1% |
| Neutropenia |
13.4% |
| Febrile Neutropenia |
6.9% |
| Diarrhoea |
5.6% |
| Thrombocytopenia |
4.0% |
| Pneumonia |
3.9% |
| Rash |
3.5% |
| Dehydration |
3.5% |
| Pulmonary Embolism |
3.3% |
| Nausea |
3.2% |
| Weight Decreased |
2.5% |
| Sepsis |
2.4% |
| Dyspnoea |
2.3% |
| Hypokalaemia |
2.3% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.2% |
| Urinary Tract Infection |
2.2% |
| Anaemia |
2.0% |
| Stomatitis |
2.0% |
| General Physical Health Deterioration |
1.9% |
|
| Secondary |
| Breast Cancer |
50.5% |
| Breast Cancer Metastatic |
18.3% |
| Product Used For Unknown Indication |
14.5% |
| Her-2 Positive Breast Cancer |
3.4% |
| Drug Use For Unknown Indication |
3.0% |
| Hypertension |
1.9% |
| Metastases To Bone |
0.8% |
| Gastric Cancer |
0.7% |
| Pancreatic Carcinoma |
0.7% |
| Prophylaxis |
0.7% |
| Disease Progression |
0.6% |
| Metastases To Central Nervous System |
0.6% |
| Ependymoma |
0.6% |
| Pain |
0.6% |
| Squamous Cell Carcinoma |
0.6% |
| Neoplasm Malignant |
0.5% |
| Ovarian Cancer |
0.5% |
| Breast Neoplasm |
0.5% |
| Colorectal Cancer |
0.4% |
| Nausea |
0.4% |
|
| Vomiting |
15.8% |
| Disease Progression |
11.0% |
| Alanine Aminotransferase Increased |
8.2% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
6.8% |
| General Physical Health Deterioration |
6.4% |
| Weight Decreased |
5.5% |
| Neutropenia |
5.3% |
| Pneumonia |
4.6% |
| Rash |
3.9% |
| Pyrexia |
3.7% |
| Aspartate Aminotransferase Increased |
3.2% |
| Death |
3.2% |
| Malignant Neoplasm Progression |
3.2% |
| Ejection Fraction Decreased |
3.0% |
| Metastases To Central Nervous System |
3.0% |
| Pleural Effusion |
3.0% |
| Atrial Fibrillation |
2.7% |
| Diarrhoea |
2.7% |
| Hypokalaemia |
2.7% |
| Multi-organ Failure |
2.3% |
|
| Concomitant |
| Breast Cancer |
31.1% |
| Breast Cancer Metastatic |
27.1% |
| Drug Use For Unknown Indication |
8.0% |
| Product Used For Unknown Indication |
7.2% |
| Neoplasm Malignant |
3.4% |
| Colon Cancer Metastatic |
3.0% |
| Metastatic Gastric Cancer |
3.0% |
| Metastases To Bone |
2.7% |
| Tension Headache |
2.0% |
| Her-2 Positive Breast Cancer |
1.8% |
| Premedication |
1.8% |
| Metastases To Liver |
1.3% |
| Prophylaxis |
1.3% |
| Metastatic Neoplasm |
1.1% |
| Invasive Ductal Breast Carcinoma |
1.0% |
| Metastases To Lung |
1.0% |
| Metastasis |
0.9% |
| Pain |
0.9% |
| Breast Cancer Female |
0.8% |
| Gastric Cancer |
0.8% |
|
| Disease Progression |
28.8% |
| Pulmonary Hypertension |
12.1% |
| Metastases To Central Nervous System |
6.1% |
| Neoplasm Malignant |
5.3% |
| Weight Decreased |
5.3% |
| Metastases To Liver |
4.5% |
| Vomiting |
4.5% |
| Malignant Neoplasm Progression |
3.8% |
| Electrocardiogram Pr Prolongation |
3.0% |
| Metastases To Bone |
3.0% |
| Metastases To Lung |
3.0% |
| Pyrexia |
3.0% |
| Death |
2.3% |
| Osteonecrosis Of Jaw |
2.3% |
| Pain In Extremity |
2.3% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.3% |
| Rash |
2.3% |
| Renal Failure |
2.3% |
| Toxicity To Various Agents |
2.3% |
| Alanine Aminotransferase Increased |
1.5% |
|
| Interacting |
| Breast Cancer |
33.3% |
| Convulsion |
33.3% |
| Metastases To Central Nervous System |
33.3% |
|
|
